Close Menu

NEW YORK – GeneproDx, a Santiago, Chile-based startup, is developing a multiplex quantitative PCR assay that it believes will help patients at risk of thyroid cancer avoid unnecessary surgery.

Publishing a pair of validation studies earlier this month on the firm’s ThyroidPrint assay, US and Chilean researchers showed they could successfully predict benign thyroid nodules with a sensitivity of 90 to 91 percent and a specificity of 87 to 89 percent.  

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.